Developability Assessment

The world needs new medicines and drug developers are racing to bring promising molecules to the market. However, drug development programs stall when:

         - Physicochemical properties of API form and formulation are uncertain

         - Lead compounds require quantifiable comparison

         - Form and formulation guesswork cause incoherent tox exposures

From lead optimization to First in Human (FIH), programs are at risk of hitting significant speed bumps if the physicochemical risks for API form and formulation are never evaluated.

Innovators need a strategic and cohesive approach to move their molecule to medicine.

Molecule to Medicine

The Mol2Med™ Developability Assessment is a dynamic, fit-for-purpose service that helps drug developers achieve a comprehensive understanding of their molecule's potential for development.

With as little as 500mg of API and 4 weeks, Crystal Pharmatech offers a smarter path forward by:

         - Determining the key physicochemical properties of your compound(s)

         - Benchmarking according to industry standards

         - Providing a high-level approach for achieving most probable success in GLP Tox and FIH